April 25, 2017
Nemaura Medical Inc. (OTCBB: NMRD), a medical device company has today announced the successful completion of the development and testing of its second-generation sugarBEAT® wireless skin-patch as a non-invasive, needle-free Continuous Glucose Monitoring (CGM) system for use by diabetics.
Nemaura Medical notes their first-generation sugarBEAT® received CE approval in Q1 2016, as a wired wrist-watch based non-invasive, needle-free CGM system.
Clinical trials on the second-generation sugarBEAT® wireless skin-patch are due to get underway soon with a view to submitting CE approval mid-year. The company expects to launch sugarBEAT® in Europe later this year through its European Licensee.
The daily-disposable format of the sugarBEAT® skin-patch is expected to provide a much more flexible way for diabetics to better manage their glucose levels. Furthermore, sugarBEAT’s® cost-effective design, consisting of a reusable Bluetooth-enabled body-worn transmitter containing a low-cost disposable adhesive skin-patch will make CGM more affordable, especially for non-insulin-injecting diabetics.
Nemaura Medical CEO Dr Faz Chowdhury said: “Adopting a wireless skin-patch format has allowed us to seamlessly integrate our needle-free technology with a diabetic’s own smart device. We have also further refined and enhanced our sensor performance, and are confident that this year’s clinical trials will confirm the efficacy of sugarBEAT® in helping to improve personal healthcare management for anyone living with diabetes. ”
Alongside the sugarBEAT® wireless skin-patch, Nemaura has also successfully developed and tested the associated sugarBEAT® mobile phone application. This Medical-grade App connects by Bluetooth to the skin-patch and displays glucose readings on a continuous basis as well as providing summary Ambulatory Glucose Profile (AGP) trends. The App also allows for additional manual lifestyle inputs helping diabetics to better understand and manage their condition.